ldp
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 27, 2019 (NCT03908814)
Timeline
Indications
Mechanism of action
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04739111 | Phase 1 | Jan 29, 2021 | Guilin Sanjin, Sichuan University |
| NCT04718584 | Phase 2 | Sep 11, 2020 | Fudan University, Guilin Sanjin |
| NCT03908814 | Phase 1 | Apr 27, 2019 | Guilin Sanjin, Huazhong University of Science and Technology |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Guilin Sanjin | For profit | 3 | 3 | 2 | 2019 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1